The six-year, 70 percent tax credit will begin in January. In return, NAMSA has agreed to maintain operations at the location for at least 10 years.
NAMSA specializes in clinical trials and product testing for all types of medical devices. The company expects increased demand from both international and domestic customers.
Related Articles on Medical Devices:
Ethicon Endo-Surgery to Acquire Reprocessor SterilMed
Small Inventors Pay Less for Fast-Track Process in New Patent Law
3 Institutions Receive $5M From FDA to Develop Pediatric Devices
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
